Wells Fargo lowered the firm’s price target on Adaptimmune (ADAP) to $1.50 from $2 and keeps an Equal Weight rating on the shares. Following Q4 results, the firm notes that U.S. Tecelra launch is actually progressing quite rapidly based on penetration rate. However, absolute patient number may be small due to the size of the indication, which requires additional time to reach breakeven, Wells says.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP: